S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
ASX:MXC

MGC Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.16 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive MXC News and Ratings via Email

Sign-up to receive the latest news and ratings for MGC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About MGC Pharmaceuticals

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.96 million
Book Value
A$0.01 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.03 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












MGC Pharmaceuticals (ASX:MXC) Frequently Asked Questions

What stocks does MarketBeat like better than MGC Pharmaceuticals?

Wall Street analysts have given MGC Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MGC Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were MGC Pharmaceuticals' earnings last quarter?

MGC Pharmaceuticals Limited (ASX:MXC) posted its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.
View MGC Pharmaceuticals' earnings history
.

Who are MGC Pharmaceuticals' key executives?

MGC Pharmaceuticals' management team includes the following people:
  • Mr. Brett Anthony Mitchell, Exec. Chairman (Age 48, Pay $260.53k)
  • Mr. Roby Reuven Zomer, Co-Founder, CEO, MD & Exec. Director
  • Mr. Nativ Segev, Founder & Non-Exec. Director
  • Mr. Daniel Kendall, Chief Financial Officer
  • Dr. Nadya Lisodover, Chief Research Officer
  • Mr. Amir Polak, CTO & Head of Pharmaceutical Production
  • Ms. Nicole Godresse, Global Chief Sales Officer
  • Ms. Sabina Suljakovic, Head of the Quality Assurance Department
  • Ms. Rachel Jelleff Kerr, Company Sec. (Leave of Absence)
  • Hugh Winters, Chief Exec. Officer of MGC Derma

What other stocks do shareholders of MGC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MGC Pharmaceuticals investors own include Triton Minerals (TON), Rox Resources (RXL), Northern Minerals (NTU), Medlab Clinical (MDC), Laneway Resources (LNY), iSignthis (ISX), Intel (INTC), Bod Australia (BDA), Azure Minerals (AZS) and AusCann Group (AC8).

What is MGC Pharmaceuticals' stock symbol?

MGC Pharmaceuticals trades on the ASX under the ticker symbol "MXC."

How much money does MGC Pharmaceuticals make?

MGC Pharmaceuticals has a market capitalization of $0.00 and generates $2.96 million in revenue each year.

How many employees does MGC Pharmaceuticals have?

MGC Pharmaceuticals employs 4 workers across the globe.

What is MGC Pharmaceuticals' official website?

The official website for MGC Pharmaceuticals is www.mgcpharma.com.au.

Where are MGC Pharmaceuticals' headquarters?

MGC Pharmaceuticals is headquartered at 415 W Wall St Ste 475, Midland, Texas 79701-4482.

How can I contact MGC Pharmaceuticals?

MGC Pharmaceuticals' mailing address is 415 W Wall St Ste 475, Midland, Texas 79701-4482. The company can be reached via phone at 61 8 6382 3390.


This page was last updated on 10/21/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.